EMEA-000371-PIP02-09

  • Email
  • Help

Overview

Product details for Revlimid
Invented nameRevlimid
Active substance

Lenalidomide

Decision numberP/50/2011
PIP numberEMEA-000371-PIP02-09
Pharmaceutical form(s)Capsule, hard
Condition(s)/indication(s)

Treatment of diffuse large B-cell lymphoma

Route(s) of administrationOral use
PIP applicant

Celgene Europe Ltd.
medinfo.intl@celgene.com
Switzerland
+41 327298500
+41 327298508

Decision typeW: decision granting a waiver in all age groups for the listed condition(s)

Decision